Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00593099 · ClinicalTrials.gov registry record · Phase 1
A Preliminary Study of Sustained-Release Bupropion for Smoking Cessation in Bipolar Affective Disorder
A Phase 1 study, sponsored by National Institute on Drug Abuse (NIDA).
- Completed
- Registry status
- Phase 1
- Development phase
- 5
- Enrollment target
NCT00593099 is a Phase 1 study that has completed, run by National Institute on Drug Abuse (NIDA). The registered enrollment target is 5 participants.
The verdict
NCT00593099, a Phase 1 study, has completed, sponsored by National Institute on Drug Abuse (NIDA).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 5 participants
- Enrollment target
Study Summary
The purpose of this pilot study is to determine the safety and potential efficacy of sustained-release bupropion (Zyban®) for the treatment of nicotine dependence in patients with bipolar affective illness. It is hypothesized that bupropion will produce a significant enhancement of smoking abstinence compared to placebo and will be safe for use in these patients.
Interventions
- DRUG Placebo
- DRUG Bupropion
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2004-04 |
| Est. Completion | 2006-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00593099
The ClinicalTrials.gov registry entry for NCT00593099 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute on Drug Abuse (NIDA), which has 335 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00593099 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00593099 about?
NCT00593099 is a clinical study titled "A Preliminary Study of Sustained-Release Bupropion for Smoking Cessation in Bipolar Affective Disorder". The purpose of this pilot study is to determine the safety and potential efficacy of sustained-release bupropion (Zyban®) for the treatment of nicotine dependence in patients with bipolar affective illness. It is hypothesized that bupropion will produce a significant enhancement of smoking abstinenc...
What is the current status of trial NCT00593099?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 5 participants. The study started on 2004-04. Estimated completion is 2006-06.
What interventions are being tested in trial NCT00593099?
The interventions under investigation include: Placebo (DRUG), Bupropion (DRUG).
Who is sponsoring clinical trial NCT00593099?
This trial is sponsored by National Institute on Drug Abuse (NIDA), which has 335 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.